The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.
Michael F. Press
Consultant or Advisory Role - GlaxoSmithKline; GlaxoSmithKline; Halozyme Therapeutics ; Halozyme Therapeutics ; Roche; Roche
Honoraria - GlaxoSmithKline; GlaxoSmithKline; Halozyme Therapeutics ; Halozyme Therapeutics ; Roche; Roche
Research Funding - Dendreon; Dendreon; GlaxoSmithKline; GlaxoSmithKline; Roche; Roche
Peter H. O'Donnell
Honoraria - Dendreon
Elizabeth R. Plimack
Honoraria - Dendreon
Leonard G. Gomella
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Research Funding - Dendreon
David I. Quinn
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Padmanee Sharma
Consultant or Advisory Role - Dendreon
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Robert Brownell Sims
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Melissa Chen
Employment or Leadership Position - Dendreon; Dendreon
Dean F. Bajorin
Consultant or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer
Honoraria - Lilly; Lilly
Research Funding - Amgen; Amgen; Amgen; Dendreon; Dendreon; Dendreon; Genentech; Genentech; Genentech; Genta; Novartis; Novartis; Novartis